InflaRx NV
NASDAQ:IFRX
InflaRx NV
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Clinical Results: InflaRx reported that long-term treatment with IFX-1 in the SHINE study led to a marked and durable improvement of inflammatory lesions in HS patients, with over 70% of initial responders maintaining response at 9 months.
Nonresponder Improvement: Placebo and minimal-dose nonresponders who switched to IFX-1 medium dose in the open-label extension showed significant lesion improvement, raising the overall 9-month response rate to 56.3%.
Safety: IFX-1 was well tolerated with no drug-related serious adverse events reported in the open-label extension phase.
Financial Position: InflaRx ended September 2019 with EUR 135.5 million in cash and securities, giving the company a self-described 3-year runway to execute its strategy.
Strategic Update: The company is expanding its clinical programs into new indications, including pyoderma gangrenosum and an upcoming oncology trial, and plans to broaden its R&D pipeline beyond anti-C5a technology.
Regulatory Path: InflaRx plans to engage with regulators in the coming months to discuss next steps, including potential alternative endpoints for future trials.
